The hemophilia clinical trial pipeline is rapidly expanding, with over 50 companies developing more than 55 drugs targeting hemophilia. Key players like Novo Nordisk, Roche, and Regeneron are advancing therapies including gene editing and long-acting factor replacements. These innovations promise improved treatment options with fewer interventions, potentially transforming patient care. Upcoming clinical trials and regulatory submissions in 2026-2027 indicate continued momentum in this field.
Novo Nordisk has regained investor confidence driven by strong demand for its Wegovy weight loss pill, which is helping stabilize its market share. While the company expects a 7% sales decline in 2024 due to U.S. pricing pressures, its international ...
Novo Nordisk reported a decline in adjusted sales and operating profit for Q1 2026, yet its obesity care segment, particularly the Wegovy pill, showed strong growth and outperformed competitors like Eli Lilly. The company benefits from patent protect...
At the American Diabetes Association conference, leading drugmakers like Eli Lilly and Novo Nordisk showcased new obesity treatments including advanced GLP-1 pills and shots promising greater weight loss and easier dosing schedules. Eli Lilly's exper...
Eli Lilly reported a strong Q1 2026 with revenue up 55.5%, driven by its obesity drug Mounjaro and new oral GLP-1 pill Foundayo, raising its full-year guidance. In contrast, Novo Nordisk saw a 4% adjusted sales decline, job cuts, and challenges inclu...
